Biocept Inc
NASDAQ:BIOC
Biocept Inc
Revenue
Biocept Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Biocept Inc
NASDAQ:BIOC
|
Revenue
$25.9m
|
CAGR 3-Years
67%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Biocept Inc
Revenue Breakdown
Breakdown by Geography
Biocept Inc
Breakdown by Segments
Biocept Inc
Total Revenue:
25.9m
USD
|
Commercial Revenues:
25.6m
USD
|
Development Services Revenues:
240k
USD
|
Kits And Specimen Collection Tubes (Scts):
2k
USD
|
See Also
What is Biocept Inc's Revenue?
Revenue
25.9m
USD
Based on the financial report for Dec 31, 2022, Biocept Inc's Revenue amounts to 25.9m USD.
What is Biocept Inc's Revenue growth rate?
Revenue CAGR 5Y
39%
Over the last year, the Revenue growth was -58%. The average annual Revenue growth rates for Biocept Inc have been 67% over the past three years , 39% over the past five years .